Kurt J. Hilzinger, Director at Outlook Therapeutics, Inc. (OTLK), bought 19,390 shares at $0.72 ($15K) on 2019-01-30, disclosed to the SEC on 2019-02-01.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.72 | 4,890 | $4K | 24.2% |
| 2 | $0.75 | 6,300 | $5K | 32.5% |
| 3 | $0.77 | 8,200 | $6K | 43.4% |
| Total | $0.75 avg | 19,390 | $15K | 100% |
| Filing → |
| OTLK | BUY | 2022-10-03 | $163K | — | Filing → |
| OTLK | BUY | 2022-03-03 | $47K | — | Filing → |
| OTLK | BUY | 2022-02-28 | $130K | — | Filing → |